Legend Biotech CEO Abruptly Resigns Without Permanent Successor
Legend Biotech CEO Ying Huang steps down. Carvykti president Alan Bash named interim CEO while search for permanent successor continues.
/ 5 items
#LEGN↓
TD Cowen Downgrades Legend Biotech After Carvykti Sales Miss
TD Cowen cut Legend Biotech to Hold from Buy after weaker Carvykti sales, citing slower demand, safety concerns, and rising competition.
FDA Signals Faster Drug Approvals for Multiple Myeloma — Positive Read for Legend Biotech
FDA draft guidance supports new approval endpoints in multiple myeloma, potentially speeding drug development and boosting prospects for Legend Biotech’s CARTITUDE-6.
Oppenheimer & H.C. Wainwright Bullish on LEGN, JBIO, CGEN
Oppenheimer and H.C. Wainwright start coverage on Legend Biotech, Jade Biosciences, and Compugen with bullish ratings and price targets, highlighting growth potential in CAR-T therapy, autoimmune, and immuno-oncology pipelines.
J&J's MajesTEC-3 Data Creates Competitive Landscape in Multiple Myeloma Treatment
Johnson & Johnson's (JNJ) Tecvayli-Darzalex combination shows strong Phase 3 results in multiple myeloma, creating competitive pressure for CAR-T therapies like Carvykti (LEGN) while offering new treatment options.